Steve Hurly, MS.c., M.B.A. is the chief executive officer and a board director at LAVA Therapeutics. He brings nearly two decades of leadership experience in the life sciences industry. He served as president and chief executive officer of Sesen Bio, a NASDAQ-listed, late-stage oncology firm. Prior he served as the president and chief executive officer of Viventia Bio Inc., a specialty pharmaceutical company acquired by Sesen Bio Inc. in September 2016. Steve has more than 15 years of experience in the investment banking business. He has served on the board of directors of PHusis Therapeutics Inc., a private targeted small molecule therapeutics company, since May 2011. Previously, he was the chief executive officer of Burrill & Co.’s merchant banking division, a finance business for life science companies. He was also the head of the life sciences investment banking practice at Boenning & Scattergood, a securities asset management and investment banking firm. He graduated from Swarthmore College with a bachelor of arts degree in engineering and earned a master of business administration from the University of Chicago.
Ton Adang, Ph.D. worked at several biotech companies and at Merck/MSD, Schering-Plough and Organon in research and development positions with increasing responsibilities. He held leadership positions in the lead discovery unit and in project management, developing a product through U.S. Food and Drug Administration approval and targeting new indications like breast cancer, osteoporosis as well as working with human vaccines, biosimilars and in immuno-oncology. He received a doctor of philosophy degree from the University of Leiden at the divisions of biopharmaceutical sciences and bio-organic chemistry.
Amy Garabedian, J.D. has extensive global and diversified legal and team building experience. During her more than 15 years practicing law, she has advised pharmaceutical & biotech companies from start-ups to multi-national public companies on the complex legal issues facing industry today. Ms. Garabedian most recently served as associate general counsel of Spark Therapeutics (Roche), where she served as a strategic and innovative advisor, playing an instrumental role in the successful U.S. launch of the first gene therapy for a genetic disease, led key business development transactions, and enabled pre-clinical, clinical and commercial product development. Earlier in her career, Ms. Garabedian held positions of increasing responsibility at Sandoz (Novartis) and as a business and finance attorney at Ballard Spahr LLP. She holds a bachelor of science degree in genetics and developmental biology from Penn State University, a master of science degree in regulatory affairs from Temple University and a juris doctor degree from Widener University Delaware School of Law.
Paul W.H.I. Parren, Ph.D., has served as LAVA Therapeutics' executive vice president and head of research and development and as a managing director since May 2018. Since January 2015, he has served as a professor of molecular immunology at the Leiden University Medical Center. Since 2013, Dr. Parren has served as a board member of The Antibody Society, for which he is the chair of the board since January 2022. He has also served as operational partner at Gilde Healthcare since December 2017 and as owner and chief executive officer of Sparring Biologics BV (Holding) and Bioconsult BV since November 2017. From 2002 to 2017, Dr. Parren served in the positions of director, vice president, senior vice president and scientific director heading Genmab’s preclinical R&D and he was an associate professor at The Scripps Research Institute in La Jolla, Calif. in 2001, where he previously served as a postdoc and assistant professor. From May 2013 to May 2018, he served as adjunct professor of translational cancer research at the University of Southern Denmark. He received his doctor of philosophy degree in molecular and biological immunology and master of science degree in experimental oncology and molecular biology with a minor in immunology from the University of Amsterdam, the Netherlands.
Hans van der Vliet, M.D., Ph.D. is chief scientific officer of LAVA Therapeutics. Dr. van der Vliet is also a professor in medical oncology at the Amsterdam UMC in the Netherlands. He received his medical doctor degree from the University of Amsterdam in 1998, his doctor of philosophy degree (cum laude) from the VU University in Amsterdam in 2003, and was trained in internal medicine, specializing in medical oncology, at the VU University medical center (currently Amsterdam UMC). He performed post-doctoral research at the division of hematology and oncology at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston.
Benjamin Winograd. M.D., Ph.D. has longstanding experience in leading drug development programs in hematology and oncology at companies including Bristol-Myers Squibb, Pharmacia, Schering-Plough and Celgene. Most recently he served as the clinical research and development therapeutic area head for multiple myeloma at Celgene where he led landmark studies resulting in the registration of lenalidomide (Revlimid) and pomalidamide (Pomalyst/Imnovid). Prior to that, he was instrumental in early and late development, registration and launching of cancer therapeutics including paclitaxel (TAXOL), irinotecan (Camptosar), exemestane (Aromasin), epirubicin (ELLENCE) and temozolomide (Temodar). He received his medical doctor degree and doctor of philospophy degree from the Technical University of Munich, Germany, and began his career as part of the EORTC cooperative group at the VU University in Amsterdam.